The Journal of Pediatrics
Volume 150, Issue 2 , Pages 134-139.e1 , February 2007

Efficacy and Safety of Extended Release Metoprolol Succinate in Hypertensive Children 6 to 16 Years of Age: A Clinical Trial Experience

Received 2 June 2006 ,Revised 24 July 2006 ,Accepted 18 September 2006.

References 

  1. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113:475–482
  2. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–576
  3. Hanevold C, Waller J, Daniels S, Portman R, Sorof J. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics. 2004;113:328–333
  4. Daniels SR, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation. 1998;97:1907–1911
  5. Newman WP, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis (The Bogalusa Heart Study). N Engl J Med. 1986;314:138–144
  6. Daniels SR. Hypertension-induced cardiac damage in children and adolescents. Blood Press Monit. 1999;4:165–170
  7. McCarron P, Smith GD, Okasha M, McEwen J. Life course exposure and later disease: a follow-up study based on medical examinations carried out in Glasgow University (1948-68). Public Health. 1999;113:265–271
  8. Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42:870–880
  9. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16:795–800
  10. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18:183–190
  11. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353–359
  12. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17:345–350
  13. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics. 1996;98:649–658
  14. Sorof JM, Poffenbarger T, Franco K, Bernard L, Portman RJ. Isolated systolic hypertension, obesity, and hyperkinetic hemodynamic states in children. J Pediatr. 2002;140:660–666
  15. Hainer J, Papademetriou V, Sugg J, et al. Metoprolol succinate extended release: Antihypertensive dose response characteristics. Am J Hypertension. 2005;18:A88;Abstract
  16. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. 2003;18:548–553
  17. Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?. Hypertension. 2004;44:289–293
  18. Flynn JT. Differentiation between primary and secondary hypertension in children using ambulatory blood pressure monitoring. Pediatrics. 2002;110:89–93
  19. Flynn JT, Alderman MH. Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol. 2005;20:961–966
  20. Flynn JT. Ethics of placebo use in pediatric clinical trials: the case of antihypertensive drug studies. Hypertension. 2003;42:865–869

 AstraZeneca LP provided support for this study.Toprol-XL and Seloken ZOK are registered trademarks of the AstraZeneca group of ompanies.Clinicaltrials.gov Identifiers: NCT00255502 and NCT00255528.

PII: S0022-3476(06)00922-X

doi: 10.1016/j.jpeds.2006.09.034

The Journal of Pediatrics
Volume 150, Issue 2 , Pages 134-139.e1 , February 2007

Article Tools

* Image Usage & Resolution